MacroGenics, I-Mab team up to develop & market enoblituzumab in China
Category: #health  By Paroma Bhattacharya  Date: 2019-07-12
  • share
  • Twitter
  • Facebook
  • LinkedIn

MacroGenics, I-Mab team up to develop & market enoblituzumab in China

MacroGenics, Inc. and I-Mab Biopharma, a U.S. and China based clinical-stage biopharmaceutical company that is committed to discover and develop biologics in autoimmune and immune-oncology diseases, have recently announced that they have inked an exclusive license agreement through which the companies will collaborate to develop and commercialize enoblituzumab.

Apparently, the investigational drug is anti-B7-H3, an immune-optimized, monoclonal antibody which incorporates proprietary Fc Optimization tech platform of MacroGenics. Enoblituzumab is among the most advanced development programs directed against B7-H3 under development, as not agent has been approved yet for the target. The regional development and commercialization rights are now owned by I-Mab for Hong Kong, Taiwan, Macau and China.

According to sources, I-Mab will be participating in the global studies conducted by MacroGenics, besides leading the regional studies as part of the collaboration. MacroGenics will be initiating enoblituzumab’s Phase 2 study combined with MGA012, an anti-PD-1 antibody which MacroGenics has licensed to Incyte Corporation, in patients with neck and head cancer later in the year.

President and CEO of MacroGenics, Scott Koenig, M.D., Ph.D., said that the company is looking forward to working with I-Mab and the partnership will broaden and accelerate the enoblituzumab development as well as support the company’s mission to bring innovative medicines to patients having unmet medical needs.

Owing to I-Mab’s track record of quickly progressing immuno-oncology programs and its ability to reach into the expanding pharmaceutical market in the region, the company believes it to be an ideal partner, Koenig added.

Reportedly, the collaboration will fetch MacroGenics an upfront payment of $15 million. It will also benefit from the eligibility to receive additional payments of $135 million for development and regulatory milestones. Additionally, I-Mab will be expected to pay tiered double-digit royalties of up to twenty percent, based on the net territory sales annually.

Source Credit- http://ir.macrogenics.com/news-releases/news-release-details/macrogenics-and-i-mab-announce-exclusive-collaboration-and



About Author

Paroma Bhattacharya

Email: [email protected]   

Paroma Bhattacharya

Paroma currently works as a content developer for Algosonline, MSF and a series of alike platforms. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched ...

Read More

More News By Paroma Bhattacharya

Mirati Therapeutics reveals Phase ½ results of KRAS inhibitor therapy
Mirati Therapeutics reveals Phase ½ results of KRAS inhibitor therapy
By Paroma Bhattacharya

Mirati Therapeutics, an oncology company that engages in the development of targeted therapies, recently released its clinical trial results for MRTX849. Reportedly, MRTX849 is a KRAS G12C inhibitor and the data from P...

Best Buy to offer free next-day delivery feature on various products
Best Buy to offer free next-day delivery feature on various products
By Paroma Bhattacharya

Online retailers are always launching new and attractive deals during the holiday season, as it grosses the highest sale time for the year. Several retailer rollout out attractive offers, such as discounts or complimen...

Nature Tech Corp partners with Aldevron for gene therapy manufacturing
Nature Tech Corp partners with Aldevron for gene therapy manufacturing
By Paroma Bhattacharya

The global cell and gene therapy sector is expected to witness a thriving period of growth over the forthcoming years. In fact, owing to the favorable growth conditions across the industry, numerous biotechnology and p...